Form 4: Bausch + Lomb Executive Receives RSU Grant

Andrew J. Stewart, President, GPIC of Bausch + Lomb Corporation, was granted 32,710 restricted share units as part of the company's 2022 Omnibus Incentive Plan.

Summary

• Andrew J. Stewart, President, GPIC of Bausch + Lomb Corporation (BLCO), was granted 32,710 restricted share units (RSUs).
• The grant was made on February 25, 2026, under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• These RSUs are scheduled to vest one-third on each of the first three anniversaries of the grant date, subject to continued service.
• Vested RSUs will be settled in common shares, no par value, of Bausch + Lomb Corporation.
• Following this transaction, Mr. Stewart beneficially owns 95,640 common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive alignment with shareholder interests through long-term equity incentives, which is a standard and healthy corporate governance practice.

Positives

• The grant of 32,710 restricted share units to a key executive, Andrew J. Stewart, aligns management's interests with long-term shareholder value.
• The vesting schedule over three years encourages executive retention and sustained performance.

Negatives

• No direct negatives are indicated in this routine executive compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The future outlook indicates that Andrew J. Stewart's beneficial ownership of Bausch + Lomb common shares will increase as the granted restricted share units vest one-third annually over the next three years, subject to his continued service.

Management Comments

• No direct management comments or quotes are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that the grant of restricted share units (RSUs) to key executives like Andrew J. Stewart is a standard practice in the pharmaceutical and medical device industry, including companies such as Johnson & Johnson or Medtronic, to incentivize long-term performance and align executive interests with shareholder returns. This type of compensation structure is widely adopted to retain talent and foster commitment to the company's strategic objectives.

Comparison to Industry Standards

• The grant of RSUs with a multi-year vesting schedule is a common and competitive executive compensation practice across the healthcare and life sciences sectors, comparable to plans seen at companies like Abbott Laboratories or Stryker Corporation.
• The 'no par value' common shares are typical for many corporations, and the $0 transaction price for a grant of RSUs is standard, reflecting that these are performance or retention incentives rather than a purchase.

Corporate Governance

Related Party Transactions

• No related party transactions are disclosed beyond the executive compensation detailed.

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of a key executive with shareholders, potentially leading to better long-term performance.
• Employees: This filing pertains specifically to executive compensation and does not directly impact the broader employee base.

Next Steps

• Vesting of one-third of the granted RSUs on February 25, 2027.
• Vesting of another one-third of the granted RSUs on February 25, 2028.
• Vesting of the final one-third of the granted RSUs on February 25, 2029.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not contain information that would fundamentally alter the investment thesis for Bausch + Lomb Corporation. It reinforces executive alignment but does not provide new operational or financial data to warrant a change in recommendation.

Keywords

Bausch + Lomb Corporation, BLCO, Restricted Share Units, RSU, Executive Compensation, Insider Transaction, Stock Grant, Andrew J. Stewart, Omnibus Incentive Plan